Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

US sues Rite Aid for missing opioid red flags

Published 03/13/2023, 04:43 PM
Updated 03/14/2023, 12:32 PM
© Reuters.

By Jonathan Stempel

WASHINGTON (Reuters) - The U.S. government on Monday sued Rite Aid (NYSE:RAD) Corp, accusing the pharmacy chain of missing "red flags" as it illegally filled hundreds of thousands of prescriptions for controlled substances, including opioids.

In a complaint filed in Cleveland federal court, the Department of Justice said Rite Aid repeatedly filled prescriptions from May 2014 to June 2019 that were medically unnecessary, for off-label use, or not issued in the usual course of professional practice.

"The Justice Department is using every tool at our disposal to confront the opioid epidemic that is killing Americans and shattering communities across the country," Attorney General Merrick Garland said in a statement.

Rite Aid pharmacists were accused of ignoring obvious signs of misuse, including in prescriptions for "trinities," a combination of opioids, benzodiazepine, and muscle relaxants preferred by drug abusers for their increased euphoric effect.

The Justice Department also said Rite Aid intentionally deleted some pharmacists' internal warnings about suspicious prescribers, such as "cash only pill mill???", while admonishing them to "be mindful of everything that is put in writing."

"These practices opened the floodgates for millions of opioid pills and other controlled substances to flow illegally out of Rite Aid's stores," Associate Attorney General Vanita Gupta said.

Rite Aid is one of the country's largest pharmacy chains, with more than 2,330 stores in 17 U.S. states. It did not immediately respond to requests for comment.

The Justice Department accused Rite Aid of violating the federal False Claims Act by submitting false prescription claims to government healthcare programs such as Medicare and Medicaid.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

It joined a whistleblower lawsuit filed in 2019 by two pharmacists and a pharmacy technician from Rite Aid stores in Pennsylvania, North Carolina and West Virginia.

The Justice Department occasionally joins whistleblower cases it considers stronger.

It has also sued Walmart (NYSE:WMT) Inc and drug distributor AmerisourceBergen (NYSE:ABC) Corp over their alleged roles in the nation's opioid crisis.

More than 500,000 people died from drug overdoses in the United States from 1999 to 2020, including more than 90,000 in 2020 alone, according to the U.S. Centers for Disease Control and Prevention.

The case is U.S. ex rel White et al v Rite Aid Corp et al, U.S. District Court, Northern District of Ohio, No. 21-01239.

Latest comments

How absurd! what exactly is the US government looking to get from a $160M cap company at this point? To bankrupt them?!? that will surely show RAD a lesson and in the process potentially force thousands of people to be unable to get any of their prescriptions filled due to a lack of pharmacies in their neighborhoods - sounds like a brilliant idea!
good thing the FDA and the dea didn't miss the red flags.....oh wait they did
of course blame everyone but yourself
how does Walmart get affected by this 🤣
good for US!
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.